Joint Gynecologic Oncology Group (GOG)-Foundation and European Network of Gynaecological Oncological Trial Groups (ENGOT) Clinical Trials Guidance for Operations with Industry Partners

<h2>Abstract</h2><h3>Background</h3> The GOG Foundation (GOG) and the European Network of Gynaecological Oncological Trial Groups (ENGOT) have collaborated on industry-partnered gynecologic oncology trials since the formation of their joint Liaison Committee in 2016. Their 2019 joint publication established shared requirements for trial sponsorship, conduct, and authorship. Since then, the scope and global complexity of co-branded trials has grown substantially, with an increasing number of third-party cooperative groups and consortia participating alongside GOG and ENGOT, and with an expanded volume of secondary and ancillary publications arising from major trials. <h3>Purpose</h3> To address these evolving needs, the GOG/ENGOT Liaison Committee has developed updated publication and authorship guidelines (Version 2.0), replacing and substantially expanding the authorship provisions of the 2019 framework. <h3>Summary Key updates include</h3> Formalization of the Third-Party Group (TPG) designation for non-GOG/non-ENGOT cooperative participants; detailed accrual-based authorship calculation and positioning rules for primary and secondary publications; guidance on ancillary and translational research authorship; conference presentation rotation; and explicit governance provisions for enrollment-related exceptions and deviations from these guidelines. <h3>Conclusions</h3> These updated guidelines provide a transparent and equitable framework for publication and authorship in GOG-ENGOT industry-partnered trials, reinforcing scientific integrity, encouraging broad participation, and supporting the responsible dissemination of results in gynecologic oncology.